BOULDER, Colo., April 15 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH - News) today announced the results of new preclinical studies of TPI 287 at the 2007 Annual Meeting of the American Association for Cancer Research (AACR). The data demonstrated that TPI 287, an orally available next-generation taxane, crosses the blood-brain barrier in rodents and demonstrates single agent activity and additive activity with temozolomide in an orthotopic model of glioblastoma. In addition, the drug demonstrated significant cytotoxic activity when administered either orally or intravenously.
